non-small cell lung cancer
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
ChromaCode, MedGenome Ink India, Middle East Distribution Deal
The deal between the US-based firms will expand availability of ChromaCode's PCR platform and a non-small cell lung cancer assay on the platform.
Agilent, PathAI Forge Deal on Algorithm-Supported Assay Development
The firms said AI-powered companion diagnostic and digital pathology assay development are among the applications supported by the partnership.
Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.